List view / Grid view
Kymab Group Limited, a leading human monoclonal antibody biopharmaceutical group, announces the appointment of Dr Sonia Quaratino as its first Chief Medical Officer. Dr Quaratino will manage the clinical development of the Group's expanding therapeutic antibody portfolio.
The monoclonal antibody biopharmaceutical group Kymab announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.
1 December 2016 | By Niamh Louise Marriott, Digital Editor
The funds will enable Kymab to advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies, with clinical development in 2017...
18 April 2016 | By Victoria White, Digital Content Producer
Heptares and Kymab are to colllaborate to discover, develop and commercialise novel antibody therapeutics targeting a number of GPCRs...
7 September 2015 | By Victoria White
The ranking recognises Kymab’s potential for rapid future sales growth and increasing international presence...
12 January 2015 | By Kymab
Combination of Kymab’s unique antibody platform and cytokine technologies expected to deliver enhanced efficacy and tolerability...
16 December 2014 | By Kymab
Kymab, a monoclonal antibody biopharmaceutical company, founded on research from the Wellcome Trust Sanger Institute announces that it has been awarded a grant from the Wellcome Trust to lead a consortium developing new treatments in the fight against Ebola...
